Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC

Evidence for efficacy is based on the results from the RELAY study
12 Jun 2020
Anticancer agents & Biologic therapy;  Lung and other thoracic tumours

On 29 May 2020, the US Food and Drug Administration (FDA) approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.

Efficacy was evaluated in RELAY (NCT02411448), a multinational, randomised, double-blind, placebo-controlled, multicentre study in patients with previously untreated metastatic NSCLC whose tumours have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations. A total of 449 patients were randomised (1:1) to receive either ramucirumab 10 mg/kg or placebo every 2 weeks as an intravenous infusion, in combination with erlotinib 150 mg orally once daily, until disease progression or unacceptable toxicity.

The major efficacy outcome measure was progression-free survival (PFS) as assessed by the investigator (RECIST v1.1). Additional efficacy outcome measures included overall survival (OS), overall response rate (ORR), and duration of response (DoR).

Median PFS was 19.4 months in the ramucirumab plus erlotinib arm compared with 12.4 months in the placebo plus erlotinib arm (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.46, 0.76; p < 0.0001).

The ORR was 76% in the ramucirumab plus erlotinib arm and 75% in the placebo plus erlotinib arm, with median DoR of 18.0 months and 11.1 months, respectively.

At the time of the final analysis of PFS, OS data were not mature as only 26% of the deaths required for the final analysis had occurred (HR 0.83; 95% CI 0.53, 1.30).

The most common adverse reactions observed in patients treated with ramucirumab with erlotinib at a rate of ≥20% and ≥2% higher than placebo with erlotinib were infections, hypertension, stomatitis, proteinuria, alopecia, epistaxis, and peripheral oedema. The most common laboratory abnormalities at a rate of ≥20% and ≥2% higher difference in incidence between arms were increased alanine aminotransferase, increased aspartate aminotransferase, anaemia, thrombocytopenia, neutropenia, increased alkaline phosphatase, and hypokalaemia.

The recommended dose of ramucirumab for metastatic NSCLC in combination with erlotinib is 10 mg/kg every 2 weeks.

Full prescribing information for CYRAMZA is available here.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings